Search Result

Results for "

thromboembolic

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (2) 5-HT Receptor (5) Akt (2) Amino Acid Derivatives (1) AMPK (2) Antibiotic (1) Apoptosis (4) Autophagy (2) Bacterial (1) Caspase (2) COX (3) Drug Derivative (1) Drug Intermediate (1) Drug Metabolite (2) Endogenous Metabolite (1) ERK (2) Factor Xa (23) Factor XI (1) Ferroptosis (2) FXR (1) Glycoprotein VI (1) Isotope-Labeled Compounds (5) Kallikrein (1) Keap1-Nrf2 (2) MOFs (1) NF-κB (3) NO Synthase (3) P2Y Receptor (3) p38 MAPK (2) PARP (2) Phosphodiesterase (PDE) (3) PI3K (2) Prostaglandin Receptor (9) Reference Standards (11) Ser/Thr Protease (3) STING (2) Thrombin (14) Thrombopoietin Receptor (3) VEGFR (2) Xanthine Oxidase (2)
By Research Areas:	Cancer (17) Cardiovascular Disease (48) Infection (4) Inflammation/Immunology (14) Metabolic Disease (2) Neurological Disease (19)

By Targets:

11β-HSD (2)

5-HT Receptor (5)

Akt (2)

Amino Acid Derivatives (1)

AMPK (2)

Antibiotic (1)

Apoptosis (4)

Autophagy (2)

Bacterial (1)

Caspase (2)

COX (3)

Drug Derivative (1)

Drug Intermediate (1)

Drug Metabolite (2)

Endogenous Metabolite (1)

ERK (2)

Factor Xa (23)

Factor XI (1)

Ferroptosis (2)

FXR (1)

Glycoprotein VI (1)

Isotope-Labeled Compounds (5)

Kallikrein (1)

Keap1-Nrf2 (2)

MOFs (1)

NF-κB (3)

NO Synthase (3)

P2Y Receptor (3)

p38 MAPK (2)

PARP (2)

Phosphodiesterase (PDE) (3)

PI3K (2)

Prostaglandin Receptor (9)

Reference Standards (11)

Ser/Thr Protease (3)

STING (2)

Thrombin (14)

Thrombopoietin Receptor (3)

VEGFR (2)

Xanthine Oxidase (2)

By Research Areas:

Cancer (17)

Cardiovascular Disease (48)

Infection (4)

Inflammation/Immunology (14)

Metabolic Disease (2)

Neurological Disease (19)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-D0837

Imidazole 2 Publications Verification Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene	MOFs Ser/Thr Protease Thrombopoietin Receptor	Neurological Disease Inflammation/Immunology
Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG₂ and PGH₂) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CL ^Pro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .

HY-50667

Apixaban Maximum Cited Publications 13 Publications Verification BMS-562247-01	Factor Xa	Cardiovascular Disease Cancer
Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .

HY-P99415

Abelacimab MAA868	Factor Xa	Cardiovascular Disease
Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies .

HY-10264

Edoxaban 5+ Cited Publications DU-176	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_i values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research .

HY-B0366A

Cyproheptadine hydrochloride 3 Publications Verification Cyproheptadine HCl	5-HT Receptor	Cardiovascular Disease Neurological Disease Cancer
Cyproheptadine hydrochloride is a potent and orally active 5-HT_2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine hydrochloride has antiplatelet and thromboprotective activities. Cyproheptadine hydrochloride can be used for the research of thromboembolic disorders .

HY-B1622

Cyproheptadine 3 Publications Verification	5-HT Receptor Apoptosis	Cardiovascular Disease Neurological Disease Cancer
Cyproheptadine is a potent and orally active 5-HT_2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine has antiplatelet and thromboprotective activities. Cyproheptadine can be used for the research of thromboembolic disorders .

HY-10264B

Edoxaban tosylate monohydrate 5+ Cited Publications DU-176b monohydrate	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_is of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research .

HY-10264A

Edoxaban tosylate 5+ Cited Publications DU-176b	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (DU-176b) tosylate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_is of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban tosylate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban tosylate can be used for preventing thromboembolic disease research .

HY-B0531

Triflusal	COX Phosphodiesterase (PDE) NF-κB NO Synthase Prostaglandin Receptor	Infection Neurological Disease Inflammation/Immunology Cancer
Triflusal is an orally bioavailable, blood-brain barrier-permeable dual Cyclooxygenase-1 (COX-1)/cAMP phosphodiesterase inhibitor. Triflusal inhibits platelet aggregation, NF-κB activation, iNOS activity, and prostaglandin synthesis in ischaemic tissue. Triflusal stimulates neutrophil nitric oxide production, eNOS protein expression, and cNOS activity. Triflusal alleviates cerebral ischemic injury in rats and ameliorates pathological lesions and related gene expression in transgenic Alzheimer’s disease models. Triflusal can be used for the research of thromboembolic/ischemic cardiovascular and cerebrovascular diseases, and Alzheimer’s disease .

HY-15799

AZD1283	P2Y Receptor	Cardiovascular Disease
AZD1283 is a potent P2Y₁₂ receptor antagonist with a binding IC₅₀ of 11 nM and a GTPγS IC₅₀ of 25 nM. AZD1283 has excellent antiplatelet aggregation potency. AZD1283 can be used to research thromboembolic disorders .

HY-N0660

Jujuboside B	Apoptosis PARP Caspase AMPK Autophagy VEGFR Keap1-Nrf2 STING 11β-HSD Ferroptosis PI3K Akt p38 MAPK ERK	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes .

HY-B0428

Ozagrel 1 Publications Verification OKY-046	Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel (OKY-046) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA₂ and increasing the production of prostacyclin (PGI2). Ozagrel can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-138053

Ristocetin A sulfate Ristomycin III	Antibiotic	Cardiovascular Disease Infection
Ristocetin A sulfate (Ristomycin III) is a glycopeptide antibiotic that binds to von Willebrand factor (VWF) and bacterial cell wall components. Ristocetin A sulfate interferes with the biosynthesis of bacterial peptidoglycan by inhibiting transpeptidation. As an inducer of platelet adhesion and aggregation, Ristocetin A sulfate drives conformational changes by binding to the A1 domain of VWF, thereby activating downstream signaling pathways and promoting cytoskeletal rearrangement. Ristocetin A sulfate not only enhances platelet adhesion and spreading on immobilized VWF, but also induces the formation of asymmetric dimers with anticooperativity between platelets and plasma VWF. Ristocetin A sulfate is widely used in studies related to thromboembolic diseases and bacterial infections .

HY-101918

DS-1040 Tosylate	Thrombin	Cardiovascular Disease
DS-1040 Tosylate is an orally active, selective inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC₅₀s of 5.92 nM and 8.01 nM for human and rat TAFIa. DS-1040 Tosylate is a fibrinolysis enhancer for thromboembolic diseases .

HY-N6987

Licraside	FXR Factor Xa	Cardiovascular Disease Inflammation/Immunology
Licraside, found in Glycyrrhiza glabra, is a Farnesoid X receptor (FXR) activator. Licraside activates FXR to induce upregulation of SHP and BSEP, regulates bile acid homeostasis, reduces elevated biliary and serum TBA, serum ALT, AST, GGT, ALP, and TBIL levels, and attenuates liver histopathological damage. Licraside inhibits factor Xa with an IC₅₀ of 48.54 mM. Licraside can be used for the research of cholestasis and thromboembolic diseases .

HY-B0428B

Ozagrel hydrochloride 1 Publications Verification OKY-046 hydrochloride	Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel hydrochloride (OKY-046 hydrochloride) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel hydrochloride exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA₂ and increasing the production of prostacyclin (PGI2). Ozagrel hydrochloride can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-100655

O-Desmethyl apixaban	Drug Metabolite	Cardiovascular Disease
O-Desmethyl apixaban is a metabolite of Apixaban (BMS-562247-01) . Apixaban is a highly selective, reversible inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively .

HY-B0428A

Ozagrel sodium 1 Publications Verification OKY-046 sodium	Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel sodium (OKY-046 sodium) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel sodium exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA₂ and increasing the production of prostacyclin (PGI2). Ozagrel sodium can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-10264R

Edoxaban (Standard) DU-176 (Standard)	Reference Standards Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (Standard) is the analytical standard of Edoxaban. This product is intended for research and analytical applications. Edoxaban (DU-176b) is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_i values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban can be used in preventing thromboembolic disease research .

HY-50667R

Apixaban (Standard) BMS-562247-01 (Standard)	Reference Standards Factor Xa	Cardiovascular Disease Cancer
Apixaban (Standard) is the analytical standard of Apixaban. This product is intended for research and analytical applications. Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with K_i of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .

HY-50667S1

Apixaban-d3 BMS-562247-01-d₃	Isotope-Labeled Compounds Factor Xa	Others
Apixaban-d3 (BMS-562247-01-d3) is the deuterium labeled Apixaban (HY-50667) . Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with K_is of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .

HY-150682

FXIa-IN-9	Factor Xa	Cardiovascular Disease
FXIa-IN-9 (compound 3f) is a potent and selective FXIa inhibitor. FXIa-IN-9 can bind with FXIa and form hydrogen bond (human FXIa K_i: 0.17 nM, rabbit FXIa K_i: 0.5 nM). FXIa-IN-9 also has anticoagulant activity, and can be used in the research of thromboembolic diseases such as atrial fibrillation, stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism .

HY-10264S

Edoxaban-d6 DU-176-d₆	Factor Xa Thrombin	Cardiovascular Disease
Edoxaban-d₆ is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .

HY-163348

FXIIa-IN-4 1 Publications Verification	Factor Xa Thrombin	Cardiovascular Disease
FXIIa-IN-4 (compound 22) is a potent, selective human FXIIa inhibitor with the IC₅₀ of 0.032 μM, 0.30 μM, ＞50 μM for FXIIa, thrombin and FXIa, respectively. FXIIa-IN-4 can be used for study of anticoagulant .

HY-150519

FXIa/Plasma kallikrein-IN-1	Factor XI Kallikrein	Cardiovascular Disease
FXIa/Plasma kallikrein-IN-1 is an inhibitor of coagulation factor XIa (FXIa) and plasma kallikrein with K_i values of 187.70 nM and 151.6 nM, respectively. FXIa/Plasma kallikrein-IN-1 can be used in the research of thromboembolic diseases .

HY-W854549

Heparin pentasaccharide Fondaparinux free acid	Factor Xa	Cardiovascular Disease
Heparin pentasaccharide (Fondaparinux) is a chemically synthesized selective factor Xa inhibitor with anticoagulant activity. Heparin pentasaccharide can be utilized in researches related to venous thromboembolic events .

HY-10273

Atecegatran metoxil AZD0837; Atecegatran fexenetil	Thrombin	Cardiovascular Disease
Atecegatran metoxil is a oral anticoagulant, which inhibits thrombin factor II and is used in thromboembolic disorders. In vivo, Atecegatran metoxil is converted to AR-H067637, a selective and reversible direct thrombin inhibitor.

HY-111755

P2Y12 antagonist 2	P2Y Receptor	Cardiovascular Disease
P2Y12 antagonist 2 is a potent P2Y₁₂ receptor antagonist. P2Y12 antagonist 2 exhibits excellent antiplatelet aggregation potency with an IC₅₀ value of 2.94 μM as well as antithrombotic efficacy in a rat ferric chloride model. P2Y12 antagonist 2 shows a superior safety profile than Clopidogrel (HY-15283) in a rat tail-bleeding model. P2Y12 antagonist 2 can be used to research thromboembolic disorders .

HY-D0837R

Imidazole (Standard) Glyoxaline (Standard); 1,3-Diaza-2,4-cyclopentadiene (Standard)	Xanthine Oxidase Reference Standards Ser/Thr Protease Thrombopoietin Receptor	Neurological Disease Inflammation/Immunology
Imidazole (Standard) is the analytical standard of Imidazole. This product is intended for research and analytical applications. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CLPro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .

HY-179017

FXa-IN-2	Factor Xa	Cardiovascular Disease
FXa-IN-2 (Compound K3) is a reversible FXainhibitor, with an IC₅₀ value of 45.08 μM. FXa-IN-2 can be used in the research of thromboembolic diseases .

HY-10758

FXa-IN-1	Factor Xa	Cardiovascular Disease
FXa-IN-1 is a FXa inhibitor (IC₅₀: 3 nM, K_i: 0.7 nM) with respectable oral bioavailability and half-life in vivo. FXa-IN-1 can be used for thromboembolic disorders .

HY-14878

(2R)-Atecegatran (2R)-AZD-0837	Thrombin	Cardiovascular Disease
(2R)-Atecegatran ((2R)-AZD-0837; (Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-Aze-Pab)) is a thrombin inhibitor. (2R)-Atecegatran can be used in research related to thromboembolic disorders .

HY-10264C

Edoxaban hydrochloride DU-176 hydrochloride	Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban (DU-176b) hydrochloride is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with K_i values of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban hydrochloride exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban hydrochloride can be used for preventing thromboembolic disease research .

HY-163347

FXIIa-IN-3	Factor Xa	Cardiovascular Disease
FXIIa-IN-3 (Compound 8) is a potent and selective Factor XIIa (FXIIa) inhibitor, with an IC₅₀ of 0.045 μM. FXIIa-IN-3 also exhibits a substantial margin of selectivity against related serine proteases, including FXIa, FXa, and FIXa. FXIIa-IN-3 can be used for the research of thromboembolic diseases .

HY-10281

YM-60828 methanesulfonate	Factor Xa	Cardiovascular Disease
YM-60828 methanesulfonate is an orally active, selective and competitive factor Xa inhibitor with a K_i of 1.3 nM and an IC50 of 2.3 nM. YM-60828 methanesulfonate inhibits thrombus formation and platelet aggregation. YM-60828 methanesulfonate can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders .

HY-100655R

O-Desmethyl apixaban (Standard)	Reference Standards Drug Metabolite	Cardiovascular Disease
O-Desmethyl apixaban (Standard) is the analytical standard of O-Desmethyl apixaban. This product is intended for research and analytical applications. O-Desmethyl apixaban is a metabolite of Apixaban (BMS-562247-01) . Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively .

HY-125615

DMP 728 methanesulfonate	Glycoprotein VI	Cardiovascular Disease Others
DMP 728 methanesulfonate is a platelet glycoprotein (GP) IIb/IIIa receptor antagonist. DMP 728 methanesulfonate shows dose-dependent antiplatelet and antithrombotic effects. DMP 728 methanesulfonate can be used in the study of effective antithrombotic agents in thromboembolic diseases of coronary and peripheral arteries .

HY-B0366AR

Cyproheptadine hydrochloride (Standard) Cyproheptadine HCl (Standard)	Reference Standards 5-HT Receptor	Cardiovascular Disease Neurological Disease Cancer
Cyproheptadine (hydrochloride) (Standard) is the analytical standard of Cyproheptadine (hydrochloride). This product is intended for research and analytical applications. Cyproheptadine hydrochloride is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine hydrochloride has antiplatelet and thromboprotective activities. Cyproheptadine hydrochloride can be used for the research of thromboembolic disorders .

HY-B1622R

Cyproheptadine (Standard)	Reference Standards 5-HT Receptor Apoptosis	Cardiovascular Disease Neurological Disease
Cyproheptadine (Standard) is the analytical standard of Cyproheptadine. This product is intended for research and analytical applications. Cyproheptadine is a potent and orally active 5-HT_2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine has antiplatelet and thromboprotective activities. Cyproheptadine can be used for the research of thromboembolic disorders .

HY-W091734

Methyl 4-iodo-L-phenylalaninate hydrochloride	Amino Acid Derivatives	Cardiovascular Disease Neurological Disease
Methyl 4-iodo-L-phenylalaninate hydrochloride is a Phenylalaninate derivative. Methyl 4-iodo-L-phenylalaninate hydrochloride can be used for the preparation of factor XI modulators used in the research of thrombotic and thromboembolic. Methyl 4-iodo-L-phenylalaninate hydrochloride can also be used for the synthesis of compounds for the research of amyloid-related diseases, such as Alzheimer’s disease .

HY-W745430

Cyproheptadine hydrochloride-d3 Cyproheptadine HCl-d₃	Isotope-Labeled Compounds 5-HT Receptor	Cardiovascular Disease Neurological Disease Cancer
Cyproheptadine hydrochloride-d₃ (Cyproheptadine HCl-d₃) is the deuterium labeled Cyproheptadine hydrochloride (HY-B0366A). Cyproheptadine hydrochloride is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine hydrochloride has antiplatelet and thromboprotective activities. Cyproheptadine hydrochloride can be used for the research of thromboembolic disorders .

HY-10275

Atecegatran AR-H067637	Thrombin	Cardiovascular Disease
Atecegatran (AR-H067637) is an orally active competitive thrombin inhibitor with a K_i of 2-4 nM. AR-H067637 inhibits platelet activation and aggregation by blocking thrombin binding to fibrin and thrombomodulin. Atecegatran demonstrates significant anticoagulant effects in various plasma coagulation assays, with an IC₅₀ ranging from 93 to 220 nM. Atecegatran can be used in research related to thromboembolic disorders .

HY-B0428BR

Ozagrel hydrochloride (Standard) OKY-046 hydrochloride (Standard)	Reference Standards Prostaglandin Receptor	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Ozagrel hydrochloride (Standard) is the analytical reference standard of Ozagrel hydrochloride (HY-B0428B). Ozagrel hydrochloride (OKY-046 hydrochloride) is a high selective and orally active thromboxane A₂ (TXA₂) synthase inhibitor with an IC₅₀ of 11 nM. Ozagrel hydrochloride exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA₂ and increasing the production of prostacyclin (PGI2). Ozagrel hydrochloride can be used for the study of ischemic stroke, asthma and thromboembolic diseases .

HY-B0531S

Triflusal-d3	Isotope-Labeled Compounds COX NF-κB Phosphodiesterase (PDE) NO Synthase Prostaglandin Receptor	Infection Neurological Disease Inflammation/Immunology Cancer
Triflusal-d₃ is deuterium labeled Triflusal (HY-B0531). Triflusal is an orally bioavailable, blood-brain barrier-permeable dual Cyclooxygenase-1 (COX-1)/cAMP phosphodiesterase inhibitor. Triflusal inhibits platelet aggregation, NF-κB activation, iNOS activity, and prostaglandin synthesis in ischaemic tissue. Triflusal stimulates neutrophil nitric oxide production, eNOS protein expression, and cNOS activity. Triflusal alleviates cerebral ischemic injury in rats and ameliorates pathological lesions and related gene expression in transgenic Alzheimer’s disease models. Triflusal can be used for the research of thromboembolic/ischemic cardiovascular and cerebrovascular diseases, and Alzheimer’s disease .

HY-B0531R

Triflusal (Standard)	Reference Standards COX Phosphodiesterase (PDE) NF-κB NO Synthase Prostaglandin Receptor	Infection Neurological Disease Inflammation/Immunology Cancer
Triflusal (Standard) is the analytical standard of Triflusal (HY-B0531). This product is intended for research and analytical applications. Triflusal is an orally bioavailable, blood-brain barrier-permeable dual Cyclooxygenase-1 (COX-1)/cAMP phosphodiesterase inhibitor. Triflusal inhibits platelet aggregation, NF-κB activation, iNOS activity, and prostaglandin synthesis in ischaemic tissue. Triflusal stimulates neutrophil nitric oxide production, eNOS protein expression, and cNOS activity. Triflusal alleviates cerebral ischemic injury in rats and ameliorates pathological lesions and related gene expression in transgenic Alzheimer’s disease models. Triflusal can be used for the research of thromboembolic/ischemic cardiovascular and cerebrovascular diseases, and Alzheimer’s disease .

HY-W699983

Imidazole-15N2 Glyoxaline-¹⁵N₂; 1,3-Diaza-2,4-cyclopentadiene-¹⁵N₂	Isotope-Labeled Compounds Thrombopoietin Receptor Ser/Thr Protease Xanthine Oxidase	Neurological Disease Inflammation/Immunology
Imidazole- ¹⁵N₂ (Glyoxaline- ¹⁵N₂) is ¹⁵N labeled Imidazole. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG₂ and PGH₂) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CL ^Pro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .

HY-10264BR

Edoxaban tosylate monohydrate (Standard) DU-176b monohydrate (Standard)	Reference Standards Factor Xa Thrombin	Cardiovascular Disease Cancer
Edoxaban tosylate monohydrate (Standard) is the analytical standard of Edoxaban tosylate monohydrate (HY-10264B). This product is intended for research and analytical applications. Edoxaban (DU-176b) monohydrate is an orally active, highly potent, selective, and direct Factor Xa (FXa) inhibitor with Kis of 0.561 and 2.98 nM for free human FXa and prothrombinase. Edoxaban monohydrate exhibits more than 10,000-fold selectivity over other coagulation proteases. Edoxaban monohydrate can be used for preventing thromboembolic disease research .

HY-101918R

DS-1040 Tosylate (Standard)	Thrombin Reference Standards	Cardiovascular Disease
DS-1040 Tosylate (Standard) is the analytical standard of DS-1040 Tosylate (HY-101918). This product is intended for research and analytical applications. DS-1040 Tosylate is an orally active, selective inhibitor of activated thrombin-activatable fibrinolysis inhibitor (TAFIa) with IC₅₀s of 5.92 nM and 8.01 nM for human and rat TAFIa. DS-1040 Tosylate is a fibrinolysis enhancer for thromboembolic diseases .

HY-10279

YM-60828 hydrochloride	Factor Xa	Cardiovascular Disease
YM-60828 hydrochloride is an orally active, selective and competitive factor Xa inhibitor with a K_i of 1.3 nM and an IC50 of 2.3 nM. YM-60828 hydrochloride inhibits thrombus formation and platelet aggregation. YM-60828 hydrochloride can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders .

HY-10762

FXa-IN-3	Factor Xa	Cardiovascular Disease
FXa-IN-3 (compound 1a) is a potent coagulation factor Xa (FXa) inhibitor with a K_i of 43 nM. FXa-IN-3 can be used in the research of thromboembolic diseases .

Cat. No.	Product Name	Type

HY-D0837

Imidazole

2 Publications Verification

Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene

Biochemical Assay Reagents

Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG₂ and PGH₂) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CL ^Pro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .

HY-W854549

Heparin pentasaccharide Fondaparinux free acid	Biochemical Assay Reagents
Heparin pentasaccharide (Fondaparinux) is a chemically synthesized selective factor Xa inhibitor with anticoagulant activity. Heparin pentasaccharide can be utilized in researches related to venous thromboembolic events .

HY-D0837R

Imidazole (Standard)

Glyoxaline (Standard); 1,3-Diaza-2,4-cyclopentadiene (Standard)

Biochemical Assay Reagents

Imidazole (Standard) is the analytical standard of Imidazole. This product is intended for research and analytical applications. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CLPro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .

Cat. No.	Product Name	Target	Research Area

HY-W091734

Methyl 4-iodo-L-phenylalaninate hydrochloride	Amino Acid Derivatives	Cardiovascular Disease Neurological Disease
Methyl 4-iodo-L-phenylalaninate hydrochloride is a Phenylalaninate derivative. Methyl 4-iodo-L-phenylalaninate hydrochloride can be used for the preparation of factor XI modulators used in the research of thrombotic and thromboembolic. Methyl 4-iodo-L-phenylalaninate hydrochloride can also be used for the synthesis of compounds for the research of amyloid-related diseases, such as Alzheimer’s disease .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99415

Abelacimab MAA868	Factor Xa	Cardiovascular Disease
Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0660

Jujuboside B	Cardiovascular Disease Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Plants Disease Research Fields Source Classification	Apoptosis PARP Caspase AMPK Autophagy VEGFR Keap1-Nrf2 STING 11β-HSD Ferroptosis PI3K Akt p38 MAPK ERK
Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes .

HY-N6987

Licraside	Structural Classification Chalcones Flavonoids Classification of Application Fields Leguminosae Phenols Polyphenols Plants Glycyrrhiza uralensis Fisch. Inflammation/Immunology Disease Research Fields Source Classification	FXR Factor Xa
Licraside, found in Glycyrrhiza glabra, is a Farnesoid X receptor (FXR) activator. Licraside activates FXR to induce upregulation of SHP and BSEP, regulates bile acid homeostasis, reduces elevated biliary and serum TBA, serum ALT, AST, GGT, ALP, and TBIL levels, and attenuates liver histopathological damage. Licraside inhibits factor Xa with an IC₅₀ of 48.54 mM. Licraside can be used for the research of cholestasis and thromboembolic diseases .

HY-N17826

YM-254891	Structural Classification Natural Products Microorganisms Source Classification	Drug Derivative Bacterial P2Y Receptor Endogenous Metabolite
YM-254891 is a YM-254890 (HY-111557) analogue and Gαq/11 inhibitor. YM-254891 can be isolated from the fermentation broth of Chromobacterium sp. QS3666. YM-254891 inhibits ADP-induced platelet aggregation .

HY-N0660R

Jujuboside B (Standard)	Triterpenes Structural Classification other families Terpenoids Plants Source Classification	Reference Standards ERK p38 MAPK Akt PI3K 11β-HSD STING VEGFR Ferroptosis Autophagy Apoptosis Keap1-Nrf2 Caspase PARP AMPK
Jujuboside B (Standard) is the analytical standard of Jujuboside B. This product is intended for research and analytical applications. Jujuboside B is a bioactive saponin component isolated from Ziziphi Spinosae Semen (sour jujube seed), with oral efficacy and blood-brain barrier permeability. Jujuboside B induces acute leukemia cell death and drives necroptosis apoptosis by activating the RIPK1/RIPK3/MLKL pathway. Jujuboside B upregulates the expression of NOXA, PARP and caspase-3, activates AMPK, inhibits the proliferation of breast cancer cells, and induces cell apoptosis and autophagy. Jujuboside B inhibits angiogenesis and tumor growth by blocking the VEGFR-2 signaling pathway. Jujuboside B alleviates liver injury in mice by regulating the Nrf2-STING signaling pathway . Jujuboside B alleviates liver injury by regulating anti-inflammatory responses and downregulating the expression of 11β-HSD2. Jujuboside B induces ferroptosis and overcomes radioresistance in non-small cell lung cancer via the PPARγ-ATF3-Gpx4 signaling pathway. Jujuboside B exerts inhibitory effects on platelet aggregation. Jujuboside B inhibits febrile seizures by suppressing the activity of AMPA receptors. Jujuboside B reverses chronic unpredictable mild stress-promoted tumor progression by blocking the PI3K/Akt and MAPK/ERK pathways and dephosphorylating CREB signaling. Jujuboside B is applicable to related studies on acute leukemia, breast cancer, PM_2.5-induced lung injury, hepatotoxicity, liver injury, colorectal cancer, non-small cell lung cancer, thromboembolic diseases, cardiovascular diseases associated with high platelet aggregation, febrile seizures, and depressive-like phenotypes.

Cat. No.	Product Name	Chemical Structure

HY-50667S1

Apixaban-d3
Apixaban-d3 (BMS-562247-01-d3) is the deuterium labeled Apixaban (HY-50667) . Apixaban (BMS-562247-01) is a highly selective, reversible and orally active inhibitor of Factor Xa with K_is of 0.08 nM and 0.17 nM in human and rabbit, respectively . Apixaban is in development for the prevention and treatment of various thromboembolic diseases .

HY-10264S

Edoxaban-d6

Edoxaban-d₆ is deuterium labeled Edoxaban. Edoxaban (DU-176) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban is an anticoagulant agent and can be used for stroke prevention. Edoxaban is also a weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10000-fold selectivity for FXa. Edoxaban has antithrombotic properties and has potential for thromboembolic diseases treatment .

HY-W745430

Cyproheptadine hydrochloride-d3

Cyproheptadine hydrochloride-d₃ (Cyproheptadine HCl-d₃) is the deuterium labeled Cyproheptadine hydrochloride (HY-B0366A). Cyproheptadine hydrochloride is a potent and orally active 5-HT2A receptor antagonist, with antidepressant and antiserotonergic effects. Cyproheptadine hydrochloride has antiplatelet and thromboprotective activities. Cyproheptadine hydrochloride can be used for the research of thromboembolic disorders .

HY-B0531S

Triflusal-d3

Triflusal-d₃ is deuterium labeled Triflusal (HY-B0531). Triflusal is an orally bioavailable, blood-brain barrier-permeable dual Cyclooxygenase-1 (COX-1)/cAMP phosphodiesterase inhibitor. Triflusal inhibits platelet aggregation, NF-κB activation, iNOS activity, and prostaglandin synthesis in ischaemic tissue. Triflusal stimulates neutrophil nitric oxide production, eNOS protein expression, and cNOS activity. Triflusal alleviates cerebral ischemic injury in rats and ameliorates pathological lesions and related gene expression in transgenic Alzheimer’s disease models. Triflusal can be used for the research of thromboembolic/ischemic cardiovascular and cerebrovascular diseases, and Alzheimer’s disease .

HY-W699983

Imidazole-15N2

Imidazole- ¹⁵N₂ (Glyoxaline- ¹⁵N₂) is ¹⁵N labeled Imidazole. Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG₂ and PGH₂) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CL ^Pro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease .

HY-10280S

YM-60828-d3
YM-60828-d₃ is the deuterium labeled YM-60828 (HY-10280). YM-60828 is an orally active, selective and competitive factor Xa inhibitor with a K_i of 1.3 nM and an IC50 of 2.3 nM. YM-60828 inhibits thrombus formation and platelet aggregation. YM-60828 can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

thromboembolic

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products